Last updated: February 17, 2026
What Is the Drug Identified by NDC 51407-0362?
NDC 51407-0362 corresponds to Tislelizumab (BGB-A317), an immune checkpoint inhibitor developed by BeiGene. It is a monoclonal antibody targeting PD-1, primarily aimed at treating various cancers, including non-small cell lung cancer (NSCLC), gastric cancer, and other solid tumors. The drug has received regulatory approvals in China, with ongoing clinical trials in the US and Europe.
What Is the Current Market Landscape?
Competitive Position
Tislelizumab faces competition from several established PD-1/PD-L1 inhibitors:
| Drug Name |
Manufacturer |
Approved Indications |
Market Penetration |
List Price (U.S.) |
Revenue (2022) |
| Keytruda (pembrolizumab) |
Merck |
Multiple cancers |
Dominates; 50%+ global market share |
~$10,000 per dose |
$26.6 billion (2022) |
| Opdivo (nivolumab) |
Bristol-Myers Squibb |
Multiple cancers |
Significant; second after Keytruda |
~$8,500 per dose |
$9.8 billion (2022) |
| Libtayo (cemiplimab) |
Regeneron/Sanofi |
Skin and lung cancers |
Niche but growing |
~$9,000 per dose |
Data not fully available |
| Tislelizumab |
BeiGene |
China-Approved; expanding globally |
Rapid growth in China; trials in US/EU |
Not publicly listed |
Estimated $200 million+ (2022, China sales) |
Market Adoption
In China, Tislelizumab is authorized for multiple indications, including NSCLC, hepatocellular carcinoma, and esophageal squamous cell carcinoma. The drug's market share has increased due to local government support and BeiGene's market access strategies.
Globally, clinical trials are advancing, with regulatory submissions in the US, EU, and other territories. The drug’s popularity is constrained by the absence of formal approvals outside China but may expand with data supporting efficacy in other regions.
What Are the Key Market Drivers and Barriers?
Drivers:
- Expansion into global markets: Regulatory filings are anticipated to open European and US access, broadening potential revenue.
- Growing incidence of target cancers: Lung, liver, and esophageal cancers remain prevalent, creating recurring demand.
- Cost-effectiveness in China: Competitive pricing and government coverage in China boost adoption.
Barriers:
- Established competition: Keytruda and Opdivo dominate the global market with wider approval.
- Limited international approvals: Tislelizumab’s market share outside China relies heavily on ongoing trials and regulatory success.
- Pricing pressures: Price negotiations, especially in Western markets, could dampen revenue potential.
What Are the Price Projections?
Current Pricing Context
In China, BeiGene offers Tislelizumab at approximately CNY 17,000 (~$2,600) per three-dose vial, significantly lower than Western prices. In the US, comparable PD-1 therapies list around $10,000 per dose, subject to insurance negotiations and discounts.
Future Price Trends
Price trajectories are influenced by regulatory status, competitive pressures, and manufacturing costs.
| Scenario |
Price Range (U.S.) |
Timeframe |
Assumptions |
| Baseline |
~$10,000 per dose |
2023-2025 |
No significant change; maintains current pricing |
| Price reduction |
~$8,000 - $9,000 |
2024-2026 |
Competitive pressures from established rivals |
| Price increase |
~$11,000 per dose |
2025+ |
High demand in expanding indications, limited competition |
Revenue Projections
Estimate future revenues based on approval status, market penetration, and pricing:
| Year |
China Market (CNY) |
US/EU Market (USD) |
Globally (USD) |
| 2023 |
~$250 million |
N/A |
~$250 million |
| 2024 |
~$400 million |
~$150 million |
~$550 million |
| 2025 |
~$700 million |
~$300 million |
~$1 billion |
| 2026+ |
$1+ billion |
$500 million+ |
$1.5+ billion |
Note: These figures reflect percentage growth aligned with market expansion and approval milestones.
How Does Pricing Influence Market Penetration?
Pricing strategies are fundamental to market entry and expansion:
- China: BeiGene’s aggressive pricing allows high-volume sales, supported by national insurance schemes.
- Western markets: High price points necessitate value demonstration through clinical outcomes, limiting early access without payor negotiations.
- Off-label uses: Limited in Western markets due to lack of formal approvals but may create additional revenue streams if approved.
What Risks Could Impact Market and Price Forecasts?
- Regulatory delays: Extended review processes or denials in key jurisdictions could inhibit market entry.
- Clinical trial outcomes: Positive data could accelerate approvals; negative results may limit prospects.
- Competitive dynamics: Blockbuster brands like Keytruda could reduce market share for Tislelizumab.
- Pricing wars: Discounting to secure market access reduces margins and overall revenue potential.
What Strategic Actions Are Recommended?
- Accelerate regulatory dialogue in the US and Europe.
- Leverage China’s domestic market success to negotiate payor agreements elsewhere.
- Invest in head-to-head trials to demonstrate comparative efficacy.
- Monitor competitor launches and adjust pricing strategies accordingly.
Key Takeaways
- Tislelizumab’s current primary market is China, where it commands a lower price with rapid sales growth.
- Global expansion hinges on regulatory approvals and clinical trial results.
- Competition from Keytruda and Opdivo remains intense; market share gains depend on positioning and pricing.
- Price projections for US markets range between $8,000 and $11,000 per dose, with potential for revenue growing from hundreds of millions to over a billion dollars globally.
- Market penetration and revenue largely depend on achieving regulatory milestones and managing competitive dynamics.
FAQs
Q1: What indications is Tislelizumab approved for in China?
A1: Lung cancer, liver cancer, esophageal squamous cell carcinoma, among others (as of 2022).
Q2: How does Tislelizumab compare price-wise with competitors?
A2: In China, it is approximately a quarter of the US price; in the US, list prices are around $10,000 per dose compared to ~$8,500–$10,000 for competitors.
Q3: When could Tislelizumab gain approval in the US and EU?
A3: Regulatory submission timelines vary; initial US filings could occur within 1-2 years if ongoing trials are successful.
Q4: What factors could limit market growth for Tislelizumab outside China?
A4: Lack of approvals, limited clinical data, intense competition, and pricing constraints.
Q5: What is the outlook for Tislelizumab’s revenue in the next five years?
A5: Potential to exceed $1 billion globally by 2026, contingent upon successful approvals and market penetration.
Sources:
[1] BeiGene official data and biotech reports.
[2] IQVIA. Market data on immuno-oncology drugs.
[3] GlobalData. Oncology drug forecasts.
[4] US Federal Register and FDA approval documents.
